M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: Fludarabine
Drug: Novantrone
Drug: Decadron
Drug: Interferon
Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Bleomycin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Cisplatin
Drug: Ara-C
Drug: Methyl-Prednisolone
Drug: Procarbazine
Drug: Prednisone

First Posted Date: 2007-12-20

Last Posted Date: 2020-11-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 210

Registration Number: NCT00577993

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combined Treatment for Tobacco and Alcohol Use in Puerto Rico

Not Applicable

Completed

Conditions: Smoking

Interventions: Behavioral: Telephone Counseling
Behavioral: Telephone Assessments

First Posted Date: 2007-12-11

Last Posted Date: 2021-07-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 370

Registration Number: NCT00570804

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Ph II Study of Azacitidine in Myelofibrosis

Phase 2

Completed

Conditions: Myelofibrosis

Interventions: Drug: Azacitidine

First Posted Date: 2007-12-07

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT00569660

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Leukemia

Interventions: Drug: Azacitidine
Drug: Ara-C

First Posted Date: 2007-12-06

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT00569010

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Computed Tomography Urography (CTU) Vs Intravenous Urography (IVU) on Patients At Risk of Urothelial Tumors

Not Applicable

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Device: Computed Tomography Urography (CTU)
Other: Intravenous Urography (IVU)

First Posted Date: 2007-12-05

Last Posted Date: 2024-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 133

Registration Number: NCT00567684

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Phase 1

Completed

Conditions: Breast Cancer
Bone Metastases

Interventions: Drug: Dasatinib
Drug: Zoledronic Acid

First Posted Date: 2007-12-03

Last Posted Date: 2022-02-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00566618

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Erlotinib
Drug: Carboplatin
Drug: Paclitaxel
Radiation: Radiation Therapy

First Posted Date: 2007-11-26

Last Posted Date: 2019-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 68

Registration Number: NCT00563784

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Oral Valganciclovir Versus Valacyclovir

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: Valacyclovir
Drug: Valganciclovir

First Posted Date: 2007-11-22

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00562770

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Renal Cell Carcinoma

Interventions: Drug: Decitabine
Drug: Interferon Alfa-2b

First Posted Date: 2007-11-21

Last Posted Date: 2011-12-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00561912

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Quality of Life Study for Prostate Cancer Patients

Conditions: Prostate Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-11-21

Last Posted Date: 2020-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1051

Registration Number: NCT00561444

Locations: 🇺🇸
MD Anderson at Cooper, Voorhees, New Jersey, United States
🇺🇸
MD Anderson Cancer Center at Albuquerque, Albuquerque, New Mexico, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy